Altus' Trizytek achieves Ph III endpoint

USA-based Altus Pharmaceuticals says that its Phase III efficacy trial of Trizytek (porcine-free enzymes) in patients with cystic fibrosis successfully met its primary endpoint of improvement in fat absorption. The company released top-line results from its 163 patient, double-blind, placebo-controlled trial of the product, an enzyme replacement therapy for patients with pancreatic insufficiency.

Trizytek is a stable and pure combination of three active enzymes in a fixed-ratio that is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals. Altus' Phase III clinical program is the largest ever conducted to evaluate the efficacy and safety of pancreatic enzyme replacement therapy in CF patients. Detailed trial results will be presented at the North American Cystic Fibrosis Conference in October.